Skip to main content
. 2021 Mar 30;8(3):1861–1872. doi: 10.1002/ehf2.13327

Figure 3.

Figure 3

Phosphodiesterase 9A (PDE9A) expression in peripheral blood mononuclear cells (PBMNCs). (A) Quantification of PDE9A mRNA expression in PBMNCs from healthy subjects (n = 5) and patients with heart failure with reduced ejection fraction (HFrEF) (n = 22), inflammatory cardiomyopathy (iCMP) (n = 24), and heart failure with preserved ejection fraction (HFpEF) (n = 24) by reverse transcription PCR. (B) PDE9A expression in PBMNCs from patients with HFpEF (n = 24) stratified by median high‐sensitivity C‐reactive protein (hsCRP) level. (C) Effect of tumour necrosis factor‐α (TNF‐α) and interleukin‐1β (IL‐1β) on PDE9A expression in PBMNCs from patients with HFpEF (n = 5–9) after incubation for 3 or 12 h. PBS, phosphate‐buffered saline.